BioDiem Ltd. has been lucratively granted patent for BDM-I, a synthetic antimicrobial compound, reveals a recent report, the announcement for which has been made today by the company.
The report says that the granting of patent signifies that the amalgam BDM-I is now restricted to BioDiem for being used as a treatment for vulvovaginitis. Vulvovaginitis is a kind of soreness that occurs in a person's vulva or vagina.
"Europe is of course a major regulatory market and this addition to the BDM-I package helps de-risk the asset as a licensing target, increasing its value to BioDiem", said CEO Julie Phillips.
The company has collaborated with USAMRIID or the United States Army Medical Research Institute of Infectious Diseases so as to get involved in preclinical studies aimed at screening BDM-I's activity in vitro. USAMRIID is already into a study looking for its impacts on varied disease-causing agents.
Since, BDM-I has been found to be a novel compound that acts actively against a massive range of pathogenic micro-organisms like fungi and protozoa. BioDiem is now into NIAID's In Vitro Assessment for Antimicrobial Activity Service2, which as per its belief, would help assess its activities in actual.
Also, a discussion is to be held with NIAID to find how Animal Models of Infectious Disease Service3 can assist further in attaining detailed information.
Good News USA
- Vodafone NZ’s new ‘Red Home’ packages will offer UFB and 150 TV channels
- Vodafone NZ’s full-year profit plunged by more than two-thirds to $56 million
- Vodafone adding 34 European countries to ‘AU$5 per day’ international roaming option
- Telstra launches its new ‘Every Day Connect Data Share Packages’
- Voyager signs “multimillion-dollar deal” with submarine cable group Hawaiki